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In mammals, Toll-like receptors (TLRs) recognize conserved microbial
molecular signatures and induce an early innate immune response in the host.
TLR signalling is mediated by interactions between the cytosolic TIR (Toll/
interleukin-1 receptor) domains of the receptor and the adaptor proteins.
Increasingly, it is apparent that pathogens target this interaction via pathogen-
expressed TIR-domain-containing proteins to modulate immune responses. A
TIR-domain-containing protein TcpB has been reported in the pathogenic
bacterium Brucella melitensis. Studies have shown that TcpB interferes with the
TLR2 and TLR4 signalling pathways to inhibit TLR-mediated inflammatory
responses. Such interference may involve TIR–TIR-domain interactions
between bacterial and mammalian proteins, but there is a lack of information
about these interactions at the molecular level. In this study, the cloning,
expression, purification, crystallization and preliminary X-ray crystallographic
analysis of the protein construct corresponding to the TIR domain of TcpB
(residues 120–250) are reported. The crystals diffracted to 2.6 A˚ resolution, have
the symmetry of the monoclinic space group P21 and are most likely to contain
four molecules in the asymmetric unit. The structure should help in
understanding the molecular basis of how TcpB affects the innate immunity
of the host.
1. Introduction
Toll-like receptors (TLRs) recognize conserved microbial molecules
and initiate innate immune responses in mammalian hosts (Gay &
Gangloff, 2007). The C-terminal TIR domain is found in all
mammalian TLRs and several cytosolic adaptor proteins (Ve et al.,
2012). TIR-domain homodimerization or heterodimerization is
important for the activation of downstream signalling and the
induction of transcription factors such as nuclear factor-!B (NF-!B)
and interferon regulatory factors (IRFs) (Ve et al., 2012). Activation
of these transcription factors initiates pro-inflammatory cytokine
secretion, which recruits more immune cells to the site of infection
(Kawai & Akira, 2007) with the aim of clearing the pathogen threat.
A number of human TIR-domain protein structures have been
determined. The structures of the TIR domains from TLR1, TLR2,
TLR10, IL-1RAPL receptors and the adaptor proteins MAL/TIRAP
and MyD88 have been determined (Xu et al., 2000; Nyman et al.,
2008; Valkov et al., 2011; Khan et al., 2004; Ohnishi et al., 2009; Snyder
et al., 2013; Lin et al., 2012). TIR-domain-containing protein
structures have also been reported from the bacterium Paracoccus
denitrificans (PdTIR; Chan et al., 2009) and plants: Arabidopsis
thaliana (AtTIR) and the flax-resistance protein L6 (Chan et al., 2010;
Bernoux et al., 2011). All TIR domains are characterized by a glob-
ular fold containing a central core of parallel "-sheets surrounded by
#-helices and connected by loop regions (Ve et al., 2012).
Owing to the critical nature of TIR–TIR-domain interactions in
TLR-mediated signalling and inflammatory responses, this inter-
action has been the source of ‘targeting’ by pathogens as a means of
modulating the innate immune response and facilitating immune
escape (Xiao, 2010; Bowie & Unterholzner, 2008). A number of
pathogenic bacteria use TIR-domain-containing proteins to actively
interfere with TLR signalling (Rana et al., 2012). Different mechan-
isms have been proposed for the role of TIR-domain-containing
protein homologues in the interference with the host innate immune
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response (Rana et al., 2012). Newman and coworkers were first to
report the inhibitory effect of Salmonella enterica serovar Enteritidis
TIR-domain-containing protein A (TlpA) on NF-!B activation,
which was reported to interfere with the TLR4 and MyD88 signalling
pathways (Newman et al., 2006). Later studies identified two TIR-
domain-containing proteins in uropathogenic Escherichia coli (TcpC)
and Brucella melitensis (TcpB) (Cirl et al., 2008). Both TcpC and
TcpB were found to interfere with TLR2-mediated and TLR4-
mediated NF-!B activation and the secretion of pro-inflammatory
cytokines (Yadav et al., 2010; Radhakrishnan & Splitter, 2010). Co-
immunoprecipitation studies showed interaction between purified
TcpC-TIR and ectopically expressed MyD88, suggesting that direct
protein–protein interactions are implicated in the suppression of the
innate immune response (Cirl et al., 2008).
TcpB was recently reported to be involved in inhibiting the
maturation of infected dendritic cells, which consequently reduces
the production of pro-inflammatory cytokines (Salcedo et al., 2008).
The protein was suggested to mimic MAL/TIRAP by binding to the
plasma membrane via its N-terminal PIP2 (phosphatidylinositol 4,5-
bisphosphate) binding domain and competitively interacting with
MyD88 (Radhakrishnan et al., 2009). This may support the finding
by Cirl and coworkers, who reported that TcpB interacts with
endogenous MyD88 in HEK293 cells (Cirl et al., 2008). However, in
later studies Sengupta and coworkers proposed that TcpB interacts
only with MAL/TIRAP and does not interfere with MAL/TIRAP–
MyD88 interactions (Sengupta et al., 2010). It was also shown that
TcpB reduces MAL/TIRAP expression in HEK293 cells and
enhances the ubiquitination and degradation of MAL/TIRAP
(Sengupta et al., 2010). Overall, there is no agreement in the literature
as to whether TcpB interacts with the adaptor proteins (MyD88 or
Mal/TIRAP) or with the TLRs (TLR4 or TLR2) (Cirl et al., 2008;
Radhakrishnan et al., 2009; Sengupta et al., 2010; Chaudhary et al.,
2012), and this is compounded by the indirect nature of some of the
assays used.
To shed light on the molecular basis of TcpB function, we initiated
a structural analysis of this protein. Here we report the molecular
cloning, expression, purification, crystallization and preliminary
X-ray crystallographic analysis of the TIR domain from Brucella
melitensis TcpB.
2. Experimental methods
2.1. Cloning
The DNA sequences encoding residues 70–250 and 120–250 of
TcpB (hereafter referred to as TcpB!70 and TcpB!120, respec-
tively) were amplified by PCR and ligated into the pMCSG7 vector
using ligation-independent cloning (Eschenfeldt et al., 2009). The
resulting constructs included an N-terminal His6 tag followed by a
TEV protease cleavage site. The correct DNA sequences were veri-
fied by sequencing.
2.2. Protein expression and purification
TcpB!70 and TcpB!120 were expressed using the auto-induction
method (Studier, 2005). Transformed Escherichia coli BL21 (DE3)
cells were propagated at 310 K until the mid-logarithmic phase
(OD600 nm of approximately 0.8) was reached. The temperature was
then reduced to 288 K and the cells were grown overnight. The next
day, the cells were harvested by centrifugation at 7500g (JLA-9.1000
rotor, Beckman Coulter) for 10 min, resuspended in 5 ml lysis buffer
per gram of cell pellet (lysis buffer: 50 mM Tris base pH 8.0, 500 mM
NaCl, 20 mM imidazole). The cells were lysed using sonication (40%
amplitude, 10 s pulse on/10 s pulse off for 1 min at 277 K) and cell
debris was removed by centrifugation at 27 200g (JA-20 rotor,
Beckman Coulter) for 40 min. The resulting supernatant was applied
onto a HisTrap FF 5 ml column (GE Healthcare) pre-equilibrated
with lysis buffer. The bound protein was eluted using a 20–300 mM
imidazole gradient. Fractions containing the protein of interest were
pooled, buffer-exchanged into TEV cleavage buffer (50 mM Tris–
HCl pH 8.0, 250 mM NaCl, 1 mM DTT, 0.5 mM EDTA) and treated
with TEV protease overnight at 277 K. The cleaved protein was then
applied onto the HisTrap FF 5 ml column for a second time to remove
the cleaved His6 tag, the TEV protease and other contaminants. The
flowthrough was concentrated and loaded onto a Superdex 75
HiLoad 26/60 gel-filtration column (GE Healthcare) pre-equilibrated
with 50 mM HEPES pH 8.0, 250 mM NaCl, 1 mM DTT. Peak frac-
tions were pooled, concentrated (using Amicon Ultra-15 10K,
Millipore) to final concentrations of 8–10 mg ml!1 for TcpB!70 and
10–22 mg ml!1 for TcpB!120, and stored in aliquots at 193 K. The
purity of the protein was assessed using SDS–PAGE.
2.3. Crystallization, data collection and processing
Several commercially available crystallization screens including
Index, PEG/Ion and PEGRx (Hampton Research), Morpheus,
JCSG+, ProPlex and PACT Premier (Molecular Dimensions),
Systematically Controlled Crystallization Screen Set 101 (Axygen
Biosciences) and Precipitant Synergy Crystallization Screen
(Emerald BioSystems) were used to identify possible crystallization
conditions. The hanging-drop vapour-diffusion method was used at
293 K and drops were set up using a Mosquito robot (TTP LabTech,
UK) at the UQ-ROCX Diffraction Facility. Each drop consisted of
100 nl protein solution and 100 nl reservoir solution and was equili-
brated against 75 ml reservoir solution. Plates were stored in an
automated imaging system (Rock Imager, Formulatrix, USA) and
images were taken after 0, 0.5, 1, 2, 3, 5, 8, 13 and 21 d. Hits from the
initial crystallization screens were optimized by varying the protein
concentration, the precipitant concentration and the pH.
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Figure 1
SDS–PAGE analysis of purified TcpB!70 (a) and TcpB!120 (b) following a two-
step chromatography purification. Lane M contains molecular-mass markers
(labelled in kDa).
Several cryoprotectants were selected from Kempkes et al. (2008).
PEG 3350, PEG 400, glycerol and MPD were tested for successful
vitrification. Glycerol was the best and it was used for crystal cryo-
preservation. Single crystals of TcpB!70 and TcpB!120 were
mounted in nylon loops and soaked in mother-liquor solution
containing #25% glycerol prior to flash-cooling in liquid nitrogen.
X-ray data were only collected from a TcpB!120 crystal under
cryogenic conditions (100 K) on the Australian Synchrotron MX2
beamline using a wavelength of 0.953693 A˚. The crystal-to-detector
distance was set to 399 mm and 360 images were collected with an
oscillation range of 1.0$. The data were collected using the Blu-Ice
software (McPhillips et al., 2002); XDS (Kabsch, 2010) and SCALA
(within the CCP4 suite; Winn et al., 2011) were used for data
indexing/integration and scaling, respectively.
3. Results and discussion
Several TcpB TIR-domain constructs were screened for expression
and solubility. Constructs encompassing amino-acid residues 70–250
(TcpB!70) and 120–250 (TcpB!120) were successfully expressed as
soluble proteins in E. coli and were purified to homogeneity using a
combination of immobilized metal-ion affinity chromatography and
gel filtration. The purity of both proteins was approximately 95% as
observed by SDS–PAGE (Fig. 1). Initial crystallization screening was
carried out using a protein concentration of #10 mg ml!1 for both
TcpB!70 and TcpB!120. Crystallization screening led to several
promising conditions for TcpB!70 but not TcpB!120. Therefore,
crystal optimization was carried out using TcpB!70.
The best initial hit for TcpB!70 corresponded to Morpheus
condition D5. The crystals had a needle-like shape and grew in
clusters. Optimization was carried out by using solutions with
different pH values (in the range pH 4–9) and different PEGs (PEG
20 000, PEG 8000, PEG 6000 and PEG 3350) at a range of concen-
trations (5–35%). Crystals grew without adding volatiles in a condi-
tion consisting of 0.1M HEPES pH 7.5, 30%(w/v) PEG 3350. In
comparison to other PEGs, PEG 3350 reduced mass nucleation.
Further optimization using micro-seeding was performed but without
success. Therefore, we screened volatile additives in the Hampton
Research Additive Screen. The crystal morphology was slightly
improved by using 2-propanol, but the clustering morphology could
not be avoided. Further optimization was carried out using solutions
with different pH values (in the range pH 4–9) and different
concentrations of PEG 3350 (5–35%) and 2-propanol (1–20%). A
single crystal (obtained by gently separating the crystal cluster),
grown using a protein concentration of 8 mg ml!1 in a condition
consisting of 0.1M HEPES pH 5.5, 30%(w/v) PEG 3350, 10%(v/v)
2-propanol (Fig. 2), was used for data collection. Unfortunately, the
crystal did not diffract beyond 8 A˚ resolution.
Additional screens were therefore performed using TcpB!120. A
large number of drops in the initial screen were clear, suggesting that
the protein concentration was too low. Therefore, we increased the
concentration of TcpB!120 to 22 mg ml!1 and repeated the initial
screening using freshly purified protein. Plate-like crystals (Fig. 3)
were observed in one condition consisting of 0.1M bis-tris pH 5.5,
0.2M NaCl, 25%(w/v) PEG 3350 (Index condition No. 70). Unfor-
tunately, these crystals could not be reproduced. The reason could be
that we used thawed protein aliquots instead of fresh protein for
crystal optimization. Therefore, we used the crystals from this
screening for X-ray data collection at the Australian Synchrotron.
A single TcpB!120 crystal (Fig. 3) diffracted to 2.6 A˚ resolution
and analysis of the diffraction data using POINTLESS (Evans, 2006)
identified a monoclinic lattice and P21 as the most likely space group
based on the analysis of systematic absences. The unit-cell parameters
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Figure 2
TcpB!70 crystal optimization. (a) Initial crystals in Morpheus (condition D5). (b) The best drop containing crystals after pH and precipitant concentration optimization
[obtained using a condition consisting of 0.1M HEPES pH 7.5, 30%(w/v) PEG 3350]. (c) Crystals after additive screening and pH optimization [obtained using a condition
consisting of 0.1M HEPES pH 5.5, 30%(w/v) PEG 3350, 10%(v/v) 2-propanol].
Figure 3
Plate-like crystals of TcpB!120 [obtained using a condition consisting of 0.1M bis-
tris pH 5.5, 0.2M NaCl, 25%(w/v) PEG 3350].
were a = 51.97, b = 73.68, c = 74.76 A˚, " = 93.29$. Data-collection
statistics are listed in Table 1. The Matthews coefficient (Matthews,
1968) was calculated to be 2.5 A˚3 Da!1 assuming the presence of four
molecules per asymmetric unit, with a solvent content of 50.7%.
We used the structure of PdTIR (PDB entry 3h16; Chan et al.,
2009) as a template model for molecular replacement in Phaser
(McCoy et al., 2007). A promising solution was found with
translation-function Z-scores above 20 and four molecules in the
asymmetric unit. Phaser generated clean density for the majority of
molecules in the asymmetric unit. However, parts of the density were
missing from all four molecules. Model building and refinement are in
progress. The structure of the TIR domain of TcpB should provide a
sound foundation for a molecular understanding of how this protein
affects the innate immune response of the host.
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Table 1
Crystal and data-collection statistics for TcpB!120.
Values in parentheses are for the outermost resolution shell.
No. of crystals 1
Beamline MX2, Australian Synchrotron
Wavelength (A˚) 0.953693
Detector ADSC Quantum 315r
Crystal-to-detector distance (mm) 339
Rotation range per image ($) 1.0
No. of images 360
Space group P21
Unit-cell parameters (A˚, $) a = 51.97, b = 73.68,
c = 74.76, " = 93.29
Molecules per asymmetric unit 4
Resolution limits (A˚) 52.43–2.71 (2.57–2.71)
No. of unique observations 18090
Completeness (%) 100.0 (99.7)
Multiplicity 3.7 (3.7)
Rmerge† (%) 8.9 (79.0)
Rp.i.m.‡ (%) 5.4 (48.3)
Average I/$(I) 10.6 (1.9)
† Rmerge =
P
hkl
P
i jIiðhklÞ ! hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the
intensity of an individual measurement of the reflection with Miller indices
hkl and hI(hkl)i is the mean intensity of that reflection. ‡ Rp.i.m. =P
hklf1=½NðhklÞ ! 1(g1=2
P
i jIiðhklÞ ! hIðhklÞij=
P
hkl
P
i IiðhklÞ.
